Skip to content
VuFind
    • English
    • Deutsch
    • Español
    • Français
    • Italiano
    • 日本語
    • Nederlands
    • Português
    • Português (Brasil)
    • 中文(简体)
    • 中文(繁體)
    • Türkçe
    • עברית
    • Gaeilge
    • Cymraeg
    • Ελληνικά
    • Català
    • Euskara
    • Русский
    • Čeština
    • Suomi
    • Svenska
    • polski
    • Dansk
    • slovenščina
    • اللغة العربية
    • বাংলা
    • Galego
    • Tiếng Việt
    • Hrvatski
    • हिंदी
    • Հայերէն
    • Українська
    • Sámegiella
    • Монгол
Advanced
  • ABTL0812 enhances antitumor ef...
  • Cite this
  • Text this
  • Email this
  • Print
  • Export Record
    • Export to RefWorks
    • Export to EndNoteWeb
    • Export to EndNote
  • Permanent link
ABTL0812 enhances antitumor effect of paclitaxel and reverts chemoresistance in triple‐negative breast cancer models

ABTL0812 enhances antitumor effect of paclitaxel and reverts chemoresistance in triple‐negative breast cancer models

Bibliographic Details
Main Authors: Emma Polonio‐Alcalá, Sònia Solé‐Sánchez, Pau Muñoz‐Guardiola, Elisabet Megías‐Roda, Héctor Perez‐Montoyo, Marc Yeste‐Velasco, Jose Alfón, Jose Miguel Lizcano, Carles Domènech, Santiago Ruiz‐Martínez, Teresa Puig
Format: Article
Language:English
Published: Wiley 2022-06-01
Series:Cancer Communications
Subjects:
ABTL0812
TRIB3
Autophagy
Breast Cancer
Targeted Therapy
Chemoresistance
Online Access:https://doi.org/10.1002/cac2.12282
  • Holdings
  • Description
  • Similar Items
  • Staff View

Internet

https://doi.org/10.1002/cac2.12282

Similar Items

  • Anticancer effects of ABTL0812, a clinical stage drug inducer of autophagy-mediated cancer cell death, in glioblastoma models
    by: Andrea Mancini, et al.
    Published: (2022-11-01)
  • Corrigendum: Anticancer effects of ABTL0812, a clinical stage drug inducer of autophagy-mediated cancer cell death, in glioblastoma models
    by: Andrea Mancini, et al.
    Published: (2025-01-01)
  • ENDOLUNG trial. A phase 1/2 study of the Akt/mTOR inhibitor and autophagy inducer Ibrilatazar (ABTL0812) in combination with paclitaxel/carboplatin in patients with advanced/recurrent endometrial cancer
    by: Alexandra Leary, et al.
    Published: (2024-07-01)
  • Correction: ENDOLUNG trial. A phase 1/2 study of the Akt/mTOR inhibitor and autophagy inducer Ibrilatazar (ABTL0812) in combination with paclitaxel/carboplatin in patients with advanced/recurrent endometrial cancer
    by: Alexandra Leary, et al.
    Published: (2024-07-01)
  • Cyclopamine reverts acquired chemoresistance and down-regulates cancer stem cell markers in pancreatic cancer cell lines
    by: J Yao, et al.
    Published: (2011-05-01)

Search Options

  • Search History
  • Advanced Search

Find More

  • Browse the Catalog
  • Browse Alphabetically
  • Explore Channels
  • Course Reserves
  • New Items

Need Help?

  • Search Tips
  • Ask a Librarian
  • FAQs